Co-Authors
This is a "connection" page, showing publications co-authored by AMY B HEIMBERGER and SHIAO-PEI WEATHERS.
Connection Strength
1.585
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.722
-
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
Score: 0.209
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.181
-
Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357.
Score: 0.146
-
GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478.
Score: 0.142
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
Score: 0.139
-
Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020 10; 8(2).
Score: 0.047